Danielle Golovin

Danielle Golovin, a Senior Biopharma Analyst specializing in induced proximity technologies, shares her insights on the evolution of next-generation targeting chimeras (TACs). She discusses the surge in publications driving this analysis and highlights specific innovations like lysosomal degraders. Steve Usdin, Washington Editor, dives into the political landscape surrounding drug pricing policies, including MFN legislation and its implications for the pharma industry. The duo also examines GSK's $2.2 billion acquisition of Rapt Therapeutics, discussing its strategic significance.